Showing posts with label Clinical. Show all posts
Showing posts with label Clinical. Show all posts

Thursday, January 19, 2017

Find Out Why You Need Clinical Hypnosis In Portland


By Elsa Noel


You need to know that your mind is the greatest source of ideas that propel your life towards the future. This suggests that you need to have the right hypnotherapy sessions that modulate your subconscious part of your mind. The hypnotherapy is crucial in the development of new emotions, responses, thoughts, attitudes and behaviors. For effective modulation and improvement of your subconscious, it is profound to visit clinical hypnosis in Portland.

One of the primary benefits of hypnotherapy is that, it helps you to manage and treat nearly all kinds of addictions, regardless of the course of the addiction. Those people who are victims of tobacco addiction, drugs food, alcohol and other substances, are likely to benefit from this form of therapy. The experts, who offer these services, are competent enough in diagnosing and choosing the best way to deal with these addictions.

It is also very important for you to know that, hypnotherapy is also crucial in enhancement of proper body weight. Those people who are struggling in regulating the weight of their body, they are advised to try this form of therapy. Most people think that, the only way to regulate body weight is through proper feeding. However, it is important to know that, this does not work for everyone. Nonetheless, hypnotherapy assists you to drop that extra body weight that might have been making you feel uncomfortable.

There are also people who experience acute pains in their body and they are always in and out of hospitals. If you are among these people, you need to know that, sharp pains are an indication that you are having chronic diseases like arthritis, migraines and fibromyalgia among other health complications. Normal pain killers and other drugs may not be very effective in reducing the pain these people experience. However, hypnotherapy seems to work best for them.

You should not allow stress to dictate the fate of your life at any moment. Stress is a major cause of various detrimental and chronic illnesses in the body. People who allow stress to occupy better part of their mind eventually suffer from conditions such as sleep disorders, diabetes, obesity, high blood pressure and cardiovascular disorders among others. Visiting hypnotic specialist could be crucial in keeping stress at bay.

People who suffer from low esteem also benefit a lot from this therapy. You cannot achieve anything important in this life if you do not have the confidence in yourself. Every remarkable progress you make depends with the level of confidence you have. Those people with low esteems, always experience problems with the way they handle their issues or even the way they relate with other people.

Enough sleep is necessary to everyone. It is therefore important for you to visit these professionals if you are experiencing sleeping disorders. These experts are experienced in helping you to solve insomnia, nightmares, wakeful sleep and sleepwalking.

Change is the only permanent thing in life. You should therefore strive to improve your behavior and even your relationship with other people. People who have problems in managing anger often find themselves doing actions that they regret later. However, once you visit these experts, you will learn how to develop the right altitude.




About the Author:




Sunday, January 15, 2017

AMD Update 9 Notal Vision’s AMD Home Monitoring Device Officially Joins AREDS2 Clinical Trial


Beginning in May, the NEI/NIH will begin recruiting 1000 patients in a cohort study, from among those participating in the AREDS2 clinical trial. Half of the recruits will be provided the Notal ForeSeeHome Device to monitor their progression from mid-to late-stage dry AMD to neovascular, or wet-stage AMD, while the other half will monitor their progress using standard care, including the Amsler Grid.

The overall objective of this two arm randomized clinical trial (RCT) is to determine if home monitoring of participants at high risk of progression to neovascular AMD, using the comprehensive visual field and telemedicine solution based on the ForeseeHome Device in AREDS2 (referred to as the ForeseeHome comprehensive solution), improves detection of progression to choroidal neovascularization (CNV) when compared with standard care (use of the Amsler Grid).

The primary outcome of this study will be to present best corrected visual acuity (BCVA) at the time of CNV diagnosis. Secondary outcomes include time to confirmed CNV diagnosis, lesion size, lesion location (extrafoveal, juxtafoveal, or subfoveal), lesion type (occult without classic, predominantly classic or minimally classic), sensitivity and specificity, and BCVA following three consecutive months of treatment and twelve months after the initial start of CNV treatment with an intravitreal anti-VEGF agent using either ranibizumab or bevacizumab.

A further secondary outcome will be to determine if vision can be preserved by earlier detection of CNV as compared to its detection at a later stage with standard care.

The study is planned to run for two years and is expected to be completed by December 2012.

(For additional information about Notal Vision and my comprehensive writeup about the ForeseeHome Device, please see: Notal Vision: The ForeseeHome AMD Monitor and It’s Potential to Save Vision – A First Report)

The official name of the clinical trial cohort is:

Home Vision Monitoring in Age-Related Eye Disease 2 (AREDS2) for Progression to Neovascular Age Related Macular Degeneration (AMD) Using the ForeseeHome Device

(A link to the web page containing additional information about the cohort study is provided above.)

Outcomes will be ascertained via the following specific aims:

Arms, Groups and Cohorts in this Clinical Trial

* : Device monitoring arm

o participants in the device monitoring arm will receive a packed device at home, with instructions to install and connect the device to a modem as well as instructions for daily use of the device.

* : Standard care (control) arm

o Standard care instruction per clinic routine for home vision monitoring (Amsler Grid) to detect progression of AMD.

Inclusion Criteria:

* Participants will be enrolled over a 9 to 12-month period and must meet the following criteria:

* 1. Male or female Age-Related Eye Disease 2 (AREDS2) participant 55 years of age or older who is actively being followed in AREDS2 and is expected to continue until the end of AREDS2.
* 2. Participant must be English speaking and understand and sign the protocol's informed consent document.
* 3. Participant does not have advanced AMD (neovascular AMD or central geographic atrophy) in at least 1 eye. The eye(s) that does not have advanced AMD must have at least intermediate AMD and will be the study eye(s).
* 4. Participant must be able to successfully demonstrate their ability to comprehend instructions and use of the ForeseeHome device (a ForeseeHome device will be available at the clinic for the participant to demonstrate their ability).
* 5. Participant must have a working phone land line in the participant's main residence.
* 6. Participant's address to which the ForeseeHome device will be sent, if randomized to the device monitoring arm, must be located in the U.S.A.
* 7. Study eye(s) must have best corrected visual acuity 20/60 or better (at least 54 letters).
* 8. Ocular media sufficient to allow adequate quality fundus photography.
* 9. Participant must be willing to have name and contact information provided to Notal Vision. Participants may be contacted as part of the study
* 10. Participant must consent to be examined by the study ophthalmologist when changes in symptoms are detected by the home-device or by standard of care or when unreliable test results occur during the usage period.
* 11. If randomized to the device monitoring arm participant must take the device with them if staying somewhere else other than their primary residence for 7 days or more.
* 12. Participant has some experience using a computer.

Exclusion Criteria:

The following are exclusion criteria for prospective study participants:

* 1. Participant has evidence of macular or retinal disorders other than AMD in the study eye(s).
* 2. Participant has known adverse reaction to fluorescein dye.
* 3. Participant is seen at the clinic more frequently than every 4 months.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 55 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No


Clinical Trial Sponsor Information

Lead Sponsor: Notal Vision Ltd


Overall Clinical Trial Officials and Contacts

Emily Chew, MD Study Chair National Eye Institute (NEI)

Overall Contact: Osnat Ehrman, MSc 952-334-5797 osnat@notalvision.com